- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
- 10-K Annual report
- 10.39 Form of Restricted Stock Grant Agreement
- 10.40 Form of Non-qualified Stock Option Grant Agreement
- 10.41 Form of Incentive Stock Option Grant Agreement
- 21.1 Subsidiary of Pro Pharmaceuticals, Inc.
- 23.1 Consent of Deloitte & Touche LLP
- 23.2 Consent of Vitale, Caturano & Company, PC
- 31.1 Certification of CEO Pursuant to Section 302
- 31.2 Certification of CFO Pursuant to Section 302
- 32.1 Certification of CEO Pursuant to Section 906
- 32.2 Certification of CFO Pursuant to Section 906
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement Nos. 333-109887, 333-115118, 333-118907, 333-111650, 333-132459, 333-148911 and 333-150898 on Form S-3 and in Registration Statement Nos. 333-116629 and 333-109893 on Form S-8 of our report dated March 28, 2008 (which report expresses an unqualified opinion and includes explanatory paragraphs relating to the Company’s adoption of Financial Accounting Standards Board (“FASB”) Interpretation (“FIN”) No. 48 “Accounting For Uncertainty in Income Taxes” on January 1, 2007, and the substantial doubt about the Company’s ability to continue as a going concern), appearing in this Annual Report on Form 10-K of Pro-Pharmaceuticals, Inc. for the year ended December 31, 2008.
/s/ Deloitte & Touche LLP
Boston, Massachusetts
March 30, 2009